Chapter 6: Parasympathetic, Neuromuscular Pharmacology, and Cholinergic Agonists

A critical component of this chapter is the detailed exploration of cholinergic neurotransmission, where acetylcholine (ACh) serves as the primary neurotransmitter. The text outlines the life cycle of ACh, including its synthesis from choline and acetate, storage in vesicles, calcium-dependent release via exocytosis, and rapid termination by the enzyme acetylcholinesterase. The mechanism of action for various toxins is also reviewed, such as botulinum toxin, which inhibits ACh release to treat muscle spasms and cosmetic wrinkles, and black widow spider venom, which induces massive ACh release. The chapter provides an in-depth classification of acetylcholine receptors into muscarinic and nicotinic types. Muscarinic receptors (M1 through M5) are G-protein coupled receptors found on smooth muscle, cardiac tissue, and glands, where they mediate effects like heart rate reduction, glandular secretion, and smooth muscle contraction via signal transduction pathways involving inositol triphosphate (IP3) or cyclic adenosine monophosphate (cAMP) inhibition. Nicotinic receptors are ligand-gated sodium channels located at neuromuscular junctions and autonomic ganglia that cause depolarization and cellular excitation upon activation. Pharmacological intervention is categorized into direct-acting and indirect-acting agonists. Direct-acting agonists include choline esters like bethanechol, used for urinary retention due to its selectivity for muscarinic receptors, and carbachol, used for ocular miosis. Natural alkaloids are also discussed, such as pilocarpine, a key treatment for glaucoma and xerostomia (dry mouth), and nicotine, used in smoking cessation therapies. Synthetic agents like cevimeline for Sjögren syndrome and varenicline, a partial agonist used to reduce smoking cravings, are also highlighted. The summary extensively covers indirect-acting agonists, primarily cholinesterase inhibitors, which amplify acetylcholine effects by preventing its breakdown. These are divided into reversible inhibitors like edrophonium, used diagnostically for myasthenia gravis, and neostigmine or pyridostigmine, which are therapeutic agents for myasthenia gravis and for reversing neuromuscular blockade after surgery. The text further examines quasi-reversible organophosphate inhibitors, such as echothiophate for glaucoma and malathion for lice, while addressing the toxicology of nerve agents and pesticides, noting that poisoning requires immediate treatment with atropine and the enzyme regenerator pralidoxime. Finally, the chapter addresses agents that modify the nitric oxide signaling pathway, specifically Type 5 phosphodiesterase (PDE5) inhibitors like sildenafil and tadalafil. These drugs treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension (PAH) by preventing the breakdown of cyclic guanosine monophosphate (cGMP), thereby promoting vasodilation. The discussion concludes with riociguat, a soluble guanylate cyclase stimulator also indicated for PAH.